AlloCure Secures $25,000,000 Series B Funding Round

  • Feed Type
  • Date
    4/2/2012
  • Company Name
    AlloCure
  • Mailing Address
    25 Corporate Dr. Burlington, MA 01803
  • Company Description
    Allocure is poised to be the first company to develop viable cell therapies for the effective treatment of many serious and debilitating medical conditions. AlloCure’s cell therapies represent a novel and proprietary class of biological therapeutics that will change the way a number of serious illnesses are treated. AlloCure’s most advanced therapies target acute kidney injury (AKI), kidney transplantation and multi organ failure. AlloCure’s Phase I Clinical Trial for AKI will begin in July of 2008.
  • Website
    http://www.allocure.com
  • Transaction Type
    M&A
  • Transaction Amount
    $25,000,000
  • Transaction Round
  • Proceeds Purposes
  • M&A Terms
    Undisclosed
  • Venture Investor
    SV Life Sciences
  • Venture Investor
    Novo A/S

By posting a comment, you agree to our terms and conditions.